Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age. Cheng-Han Chen ...

As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis (US) service reveal ...

The Company granted options to purchase 250,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $4.46, which was the closing ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets ... and cancer meds Tecentriq, a PD-1 inhibitor, and breast cancer therapy Perjeta, which earned ...

Lola Young’s ode to finding the balance in yourself, Messy, secures a second week at Number 1 in the UK. The tune became Lola’s first UK chart-topper last week, and continues to impress as ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor (DPP4i); 43,499 starting a sodium-glucose cotransporter 2 inhibitor ...

The authors used the U.S. Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated a GLP-1 RA and compared them to patients initiating sulfonylureas, dipeptidyl ...